Metagenomi (NASDAQ:MGX) Receives Buy Rating from Chardan Capital

Chardan Capital reaffirmed their buy rating on shares of Metagenomi (NASDAQ:MGX) in a report published on Thursday, Benzinga reports. They currently have a $21.00 price objective on the stock.

Several other research analysts have also recently weighed in on the stock. JPMorgan Chase & Co. started coverage on shares of Metagenomi in a report on Tuesday, March 5th. They set an overweight rating and a $16.00 price target on the stock. Wells Fargo & Company began coverage on shares of Metagenomi in a research report on Tuesday, March 5th. They issued an overweight rating and a $25.00 price objective on the stock. BMO Capital Markets began coverage on shares of Metagenomi in a research report on Tuesday, March 5th. They issued an outperform rating and a $22.00 price objective on the stock. TD Cowen began coverage on shares of Metagenomi in a research report on Tuesday, March 5th. They issued an outperform rating on the stock. Finally, Jefferies Financial Group began coverage on shares of Metagenomi in a research report on Tuesday, March 5th. They issued a buy rating and a $23.00 price objective on the stock. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Metagenomi currently has an average rating of Buy and a consensus price target of $21.40.

Metagenomi Stock Performance

Metagenomi stock opened at $10.55 on Thursday. Metagenomi has a fifty-two week low of $9.74 and a fifty-two week high of $12.74.

Insider Activity

In other Metagenomi news, major shareholder Holdings A/S Novo purchased 800,000 shares of the stock in a transaction dated Tuesday, February 13th. The shares were bought at an average price of $15.00 per share, with a total value of $12,000,000.00. Following the completion of the transaction, the insider now directly owns 1,739,175 shares in the company, valued at approximately $26,087,625. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Metagenomi Company Profile

Metagenomi, Inc, a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.